UnitedHealth Group stock declined in pre-open trading, slipping 3.17% to $381.35, after a regulatory filing from Berkshire Hathaway showed the conglomerate had fully sold its position of about 5.04 million UNH shares during the first quarter of 2026. The 13F disclosure, released after markets closed on Friday, indicates Berkshire had only first taken the UNH position in the second quarter of 2025, meaning the holding lasted under a year.
The filing places the UNH sale within a larger portfolio reshuffle overseen by Greg Abel, who became Berkshire Hathaway’s chief executive on January 1 following Warren Buffett’s step back from the role. Alongside the UnitedHealth exit, Berkshire also exited stakes in Visa, Mastercard, Amazon, and Domino’s Pizza during the same reporting period, while concurrently establishing a new position in Delta Air Lines valued at roughly $2.65 billion.
Some retail investors interpreted the UNH divestiture as a strategic reallocation of capital toward airlines rather than a direct critique of UnitedHealth’s fundamentals. Nevertheless, the timing of the sale compounds a set of pre-existing pressures facing UnitedHealth.
Those company-level headwinds include a federal moratorium that bans new Medicare enrollments for home healthcare providers, UnitedHealth’s own plan to remove 1.3 million Medicare Advantage members as a means to protect profit margins, and an unresolved U.S. Department of Justice probe into the company’s billing practices. These items represent regulatory and operational uncertainties that market participants are monitoring closely.
Investor sentiment toward UnitedHealth had improved in recent weeks after the company delivered stronger-than-expected first-quarter earnings, benefited from improved Medicare reimbursement, and offered bullish guidance that lifted confidence. The stock had been moving toward the $400 level on that momentum.
That recovery faced renewed pressure in the current pre-market session as the broader market also moved lower. The S&P 500, Dow Jones, and NASDAQ were down in pre-market trading. At the same time, the 10-year Treasury yield rose to its highest point since February 2025 and Brent crude oil traded above $110 per barrel, a rise attributed in the filing to stalled Iran peace negotiations. The combination of a notable institutional exit, lingering regulatory issues, and a risk-off macroeconomic backdrop produced an unfavorable pre-market context for UNH.
UnitedHealth’s first-quarter results had exceeded analyst expectations and management raised full-year profit guidance, a development that briefly reassured investors. The Berkshire sale and the broader market moves, however, have reintroduced selling pressure and put the recent rally to the test.
Summary
Berkshire Hathaway disclosed it sold its entire UNH stake of about 5.04 million shares in Q1 2026, a holding established in Q2 2025 and lasting under a year. The divestment coincides with regulatory challenges and a risk-off market environment that have weighed on UnitedHealth stock despite a recent earnings beat and raised guidance.
Key points
- Berkshire Hathaway fully liquidated an approximately 5.04 million-share position in UnitedHealth during Q1 2026; the position was first built in Q2 2025.
- The sale is part of a broader reallocation under CEO Greg Abel, which also included exits from Visa, Mastercard, Amazon, and Domino’s Pizza and a new roughly $2.65 billion stake in Delta Air Lines.
- UnitedHealth faces regulatory and operational pressures - a federal moratorium on new Medicare enrollments for home healthcare providers, planned removal of 1.3 million Medicare Advantage members, and an unresolved DOJ investigation - occurring alongside a weaker pre-market macro environment.
Risks and uncertainties
- Regulatory risk: The federal moratorium on new Medicare enrollments for home healthcare providers could affect enrollment trends and operations in the healthcare sector.
- Operational and reputational risk: The planned reduction of 1.3 million Medicare Advantage members and the unresolved DOJ billing investigation introduce uncertainty for UnitedHealth’s revenue and margins.
- Market risk: Broader risk-off conditions, including rising Treasury yields and higher oil prices, create a challenging environment for risk assets, including healthcare stocks.